Lysosomal Storage Diseases

Lysosomal storage diseases (LSDs) are a group of inherited disorders caused by defects in lysosomal enzymes, transporters, or related cellular pathways. Accumulation of undegraded substrates can affect multiple organs, including the nervous system, bones, liver, spleen, heart, lungs, and kidneys. Clinical presentation varies widely by disease and genotype, making timely diagnosis and coordinated care central priorities.

The LSD landscape is shifting toward earlier identification, more precise classification, and multidisciplinary long-term management. Newborn screening, expanded biochemical testing, molecular diagnostics, biomarker development, and improved imaging are helping clinicians distinguish overlapping phenotypes and identify affected relatives. Care models are also moving beyond isolated specialty visits toward coordinated pathways linking metabolic medicine, neurology, cardiology, genetics, rehabilitation, and psychosocial support.

Artificial intelligence can support LSD care by recognizing patterns across clinical records, imaging, laboratory results, genomic data, and patient-reported outcomes. Potential applications include prioritizing individuals for confirmatory testing, identifying atypical disease trajectories, improving trial recruitment, and monitoring treatment response. Responsible use requires representative datasets, clinical validation, explainability, privacy safeguards, and expert oversight because rare-disease data are often sparse, heterogeneous, and vulnerable to bias.

North America generally emphasizes specialist networks, genetic testing, newborn-screening expansion, and access coordination, while Europe is shaped by cross-border expertise, national health-technology assessment, and efforts to reduce diagnostic delay. Asia-Pacific combines advanced centers in countries such as Japan, Australia, and South Korea with substantial access variation across health systems. Latin America continues to prioritize recognition, referral capacity, and sustainable access, while the Middle East and Africa face uneven specialist availability, laboratory infrastructure, and genetic counseling coverage. Across all regions, registries, referral pathways, and locally appropriate diagnostic tools remain important enablers.

ASEAN countries can benefit from regional laboratory collaboration, shared training, and referral networks that address differences in specialist capacity. BRICS members bring diverse research, manufacturing, and public-health capabilities but require stronger interoperability and equitable access mechanisms. The European Union benefits from coordinated rare-disease frameworks and cross-border expertise, while G7 systems can advance standards for diagnostics, evidence generation, and patient-centered care. GCC countries are positioned to strengthen genomic medicine and centralized services, and NATO members may benefit from resilient supply chains, interoperable health data, and continuity planning for specialized therapies.

Australia can build on centralized expertise and geographically adapted referral models; Brazil and Mexico face priorities in earlier recognition, diagnostic reach, and continuity across unequal health systems. Canada and the United States emphasize specialist coordination, screening policy, and access navigation. China and India have opportunities to expand genomic diagnostics, registries, and trained metabolic-care capacity. France, Germany, Italy, Spain, and the United Kingdom continue to develop multidisciplinary services, evidence-based pathways, and cross-regional coordination. Japan and South Korea have strong advanced-care capabilities and can further support precision diagnostics and longitudinal monitoring. Russia’s priorities include maintaining specialist access, diagnostic capacity, and reliable continuity of care across a geographically extensive system.

Leaders should invest in validated diagnostic algorithms, clinician education, newborn-screening evidence, and referral protocols that shorten the path to confirmation. Partnerships with patient organizations and care providers can improve adherence, psychosocial support, and outcome measurement. Data strategies should use interoperable registries, transparent governance, and clinically meaningful endpoints. Organizations should also design access programs around local health-system realities, strengthen supply and treatment continuity, and evaluate artificial-intelligence tools prospectively rather than relying on unvalidated performance claims.

This executive summary uses a structured qualitative synthesis of established LSD biology, diagnostic and therapeutic practice, rare-disease policy themes, health-system capabilities, and published discussions of digital and artificial-intelligence applications. Regional, group, and country observations are framed as system-level considerations rather than quantitative market claims. Interpretations should be checked against current clinical guidelines, regulatory decisions, screening policies, epidemiological studies, patient registries, and locally applicable reimbursement rules before operational use.

Progress in lysosomal storage diseases depends on connecting scientific innovation with practical delivery. Earlier diagnosis, molecular confirmation, multidisciplinary management, robust evidence generation, and responsible data use can improve the consistency of care across diverse settings. The strongest strategies will combine local health-system adaptation with international collaboration, ensuring that advances in diagnostics and treatment translate into meaningful outcomes for patients and families.